STOCK TITAN

[POS AM] Inozyme Pharma, Inc. SEC Filing

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
POS AM
Rhea-AI Filing Summary

Inozyme Pharma, Inc. (NASDAQ: INZY) filed Post-Effective Amendment No. 1 to deregister securities remaining under two previously effective shelf Registration Statements on Form S-3 (Nos. 333-258702 and 333-275364). The shelves collectively covered up to $500 million of common stock, preferred stock, debt, depositary shares, subscription rights, warrants and units. As of July 1, 2025, none of the registered securities remain available for sale.

The amendment follows the consummation of Inozyme’s merger with BioMarin Pharmaceutical Inc. Under the Agreement and Plan of Merger dated May 16, 2025, Incline Merger Sub, Inc. merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin as of July 1, 2025. Consequently, all outstanding offerings under the shelves were terminated and the company is removing any unsold securities from registration pursuant to its undertaking under Rule 415.

This filing is largely administrative, signaling the formal close-out of Inozyme’s capital-raising capability as a standalone public entity and completing one of the final SEC steps associated with the transaction.

Inozyme Pharma, Inc. (NASDAQ: INZY) ha presentato l'Emendamento Post-Efficace n. 1 per cancellare la registrazione dei titoli residui sotto due precedenti Registrazioni a Scaffale efficaci sul modulo S-3 (Numeri 333-258702 e 333-275364). Questi scaffali coprivano complessivamente fino a 500 milioni di dollari di azioni ordinarie, azioni privilegiate, debito, azioni depositarie, diritti di sottoscrizione, warrant e unità. Al 1° luglio 2025, nessuno dei titoli registrati è più disponibile per la vendita.

L'emendamento segue il completamento della fusione di Inozyme con BioMarin Pharmaceutical Inc. In base all'Accordo e Piano di Fusione datato 16 maggio 2025, Incline Merger Sub, Inc. si è fusa con Inozyme, rendendo Inozyme una controllata interamente posseduta da BioMarin a partire dal 1° luglio 2025. Di conseguenza, tutte le offerte in corso sotto gli scaffali sono state terminate e la società sta rimuovendo i titoli invenduti dalla registrazione in conformità all'impegno previsto dalla Regola 415.

Questa presentazione è prevalentemente di natura amministrativa, segnando la chiusura formale della capacità di raccolta capitale di Inozyme come entità pubblica autonoma e completando uno degli ultimi passaggi presso la SEC relativi all'operazione.

Inozyme Pharma, Inc. (NASDAQ: INZY) presentó la Enmienda Post-Efectiva n.º 1 para cancelar la inscripción de los valores restantes bajo dos Declaraciones de Registro en Estantería anteriormente vigentes en el Formulario S-3 (Números 333-258702 y 333-275364). Estas estanterías cubrían colectivamente hasta 500 millones de dólares en acciones comunes, acciones preferentes, deuda, acciones depositarias, derechos de suscripción, warrants y unidades. A partir del 1 de julio de 2025, ninguno de los valores registrados está disponible para la venta.

La enmienda sigue a la consumación de la fusión de Inozyme con BioMarin Pharmaceutical Inc. Según el Acuerdo y Plan de Fusión fechado el 16 de mayo de 2025, Incline Merger Sub, Inc. se fusionó con Inozyme, convirtiendo a Inozyme en una subsidiaria de propiedad total de BioMarin a partir del 1 de julio de 2025. En consecuencia, todas las ofertas pendientes bajo las estanterías fueron terminadas y la compañía está retirando los valores no vendidos de la inscripción conforme a su compromiso bajo la Regla 415.

Esta presentación es principalmente administrativa, señalando el cierre formal de la capacidad de Inozyme para recaudar capital como entidad pública independiente y completando uno de los últimos pasos ante la SEC relacionados con la transacción.

Inozyme Pharma, Inc. (NASDAQ: INZY)는 이전에 유효했던 두 개의 선등록 서류(Form S-3, 번호 333-258702 및 333-275364)에 남아 있던 증권의 등록 말소를 위한 사후 효력 수정안 1호를 제출했습니다. 이 선등록은 보통주, 우선주, 채무, 예탁주식, 청약권, 워런트 및 단위 증권을 합쳐 최대 5억 달러까지 포함하고 있었습니다. 2025년 7월 1일 기준으로 등록된 증권 중 판매 가능한 증권은 남아 있지 않습니다.

이번 수정안은 Inozyme가 BioMarin Pharmaceutical Inc.와의 합병을 완료한 데 따른 것입니다. 2025년 5월 16일자 합병 계약 및 계획에 따라 Incline Merger Sub, Inc.가 Inozyme와 합병되어, 2025년 7월 1일부로 Inozyme는 BioMarin의 완전 자회사로 편입되었습니다. 이에 따라 모든 선등록 하의 미완료 발행은 종료되었으며, 회사는 Rule 415에 따라 미판매 증권을 등록에서 제거하고 있습니다.

이번 제출은 주로 행정적인 절차로, Inozyme가 독립적인 상장 기업으로서 자본 조달 능력을 공식적으로 종료했음을 알리고, 이번 거래와 관련한 SEC의 마지막 단계 중 하나를 완료하는 의미가 있습니다.

Inozyme Pharma, Inc. (NASDAQ : INZY) a déposé l'Amendement post-effectif n° 1 afin de radier les titres restants sous deux déclarations d'enregistrement sur étagère précédemment en vigueur sur le formulaire S-3 (numéros 333-258702 et 333-275364). Ces étagères couvraient collectivement jusqu'à 500 millions de dollars d'actions ordinaires, actions privilégiées, dettes, actions déposées, droits de souscription, bons de souscription et unités. Au 1er juillet 2025, aucun des titres enregistrés n'est plus disponible à la vente.

Cet amendement fait suite à la finalisation de la fusion d'Inozyme avec BioMarin Pharmaceutical Inc. Conformément à l'accord et au plan de fusion datés du 16 mai 2025, Incline Merger Sub, Inc. a fusionné avec Inozyme, faisant d'Inozyme une filiale à 100 % de BioMarin à compter du 1er juillet 2025. Par conséquent, toutes les offres en cours sous les étagères ont été terminées et la société retire les titres invendus de l'enregistrement conformément à son engagement en vertu de la règle 415.

Ce dépôt est principalement administratif, marquant la clôture officielle de la capacité d'Inozyme à lever des fonds en tant qu'entité publique indépendante et complétant l'une des dernières étapes auprès de la SEC liées à la transaction.

Inozyme Pharma, Inc. (NASDAQ: INZY) hat den Nachwirkungsänderungsantrag Nr. 1 eingereicht, um die verbleibenden Wertpapiere unter zwei zuvor wirksamen Shelf-Registrierungserklärungen auf Formular S-3 (Nummern 333-258702 und 333-275364) abzumelden. Die Shelves umfassten insgesamt bis zu 500 Millionen US-Dollar an Stammaktien, Vorzugsaktien, Schuldtiteln, Hinterlegungsscheinen, Bezugsrechten, Optionsscheinen und Einheiten. Zum 1. Juli 2025 sind keine der registrierten Wertpapiere mehr zum Verkauf verfügbar.

Die Änderung erfolgt nach dem Vollzug der Fusion von Inozyme mit BioMarin Pharmaceutical Inc. Gemäß der Fusionsvereinbarung vom 16. Mai 2025 fusionierte Incline Merger Sub, Inc. mit Inozyme, wodurch Inozyme zum 1. Juli 2025 eine hundertprozentige Tochtergesellschaft von BioMarin wurde. Folglich wurden alle ausstehenden Angebote unter den Shelves beendet und das Unternehmen entfernt unverkäufliche Wertpapiere gemäß seiner Verpflichtung unter Regel 415 aus der Registrierung.

Diese Einreichung ist überwiegend administrativer Natur und signalisiert den formellen Abschluss der Kapitalbeschaffungskapazität von Inozyme als eigenständiges börsennotiertes Unternehmen und schließt einen der letzten SEC-Schritte im Zusammenhang mit der Transaktion ab.

Positive
  • Merger with BioMarin closed on July 1, 2025, providing Inozyme’s programs access to a larger company’s resources.
  • Withdrawal of $500 million of unsold shelf securities eliminates potential future dilution for former INZY shareholders.
Negative
  • Inozyme will no longer operate as an independent public company, removing direct investment exposure for existing INZY investors.
  • Standalone capital-raising flexibility ends with the termination of both S-3 registration statements.

Insights

TL;DR: Filing removes $500 m shelf as BioMarin closes INZY acquisition; purely administrative, confirms deal completion.

The deregistration indicates the merger’s legal completion, eliminating Inozyme’s ability to independently issue additional securities. From a transaction perspective, this is standard procedure and carries minimal incremental valuation impact—deal economics were embedded when the merger terms were announced on May 16. For former INZY holders, any dilution risk from future issuances disappears, but independent upside potential also ends. Overall, the amendment confirms integration into BioMarin’s corporate structure.

TL;DR: Shelf withdrawal ends INZY’s fundraising capacity; neutral for valuation as merger already priced in.

By terminating both S-3 shelves, management removes latent supply of new shares or debt, a modest positive for dilution optics. However, because Inozyme equity will cease trading, the capital-markets implications are moot. Investors now rely on BioMarin’s balance sheet and strategy for any exposure to the acquired pipeline. No financial metrics, earn-outs, or contingent payments are disclosed in this document, so impact on BioMarin’s leverage or EPS cannot be assessed here.

Inozyme Pharma, Inc. (NASDAQ: INZY) ha presentato l'Emendamento Post-Efficace n. 1 per cancellare la registrazione dei titoli residui sotto due precedenti Registrazioni a Scaffale efficaci sul modulo S-3 (Numeri 333-258702 e 333-275364). Questi scaffali coprivano complessivamente fino a 500 milioni di dollari di azioni ordinarie, azioni privilegiate, debito, azioni depositarie, diritti di sottoscrizione, warrant e unità. Al 1° luglio 2025, nessuno dei titoli registrati è più disponibile per la vendita.

L'emendamento segue il completamento della fusione di Inozyme con BioMarin Pharmaceutical Inc. In base all'Accordo e Piano di Fusione datato 16 maggio 2025, Incline Merger Sub, Inc. si è fusa con Inozyme, rendendo Inozyme una controllata interamente posseduta da BioMarin a partire dal 1° luglio 2025. Di conseguenza, tutte le offerte in corso sotto gli scaffali sono state terminate e la società sta rimuovendo i titoli invenduti dalla registrazione in conformità all'impegno previsto dalla Regola 415.

Questa presentazione è prevalentemente di natura amministrativa, segnando la chiusura formale della capacità di raccolta capitale di Inozyme come entità pubblica autonoma e completando uno degli ultimi passaggi presso la SEC relativi all'operazione.

Inozyme Pharma, Inc. (NASDAQ: INZY) presentó la Enmienda Post-Efectiva n.º 1 para cancelar la inscripción de los valores restantes bajo dos Declaraciones de Registro en Estantería anteriormente vigentes en el Formulario S-3 (Números 333-258702 y 333-275364). Estas estanterías cubrían colectivamente hasta 500 millones de dólares en acciones comunes, acciones preferentes, deuda, acciones depositarias, derechos de suscripción, warrants y unidades. A partir del 1 de julio de 2025, ninguno de los valores registrados está disponible para la venta.

La enmienda sigue a la consumación de la fusión de Inozyme con BioMarin Pharmaceutical Inc. Según el Acuerdo y Plan de Fusión fechado el 16 de mayo de 2025, Incline Merger Sub, Inc. se fusionó con Inozyme, convirtiendo a Inozyme en una subsidiaria de propiedad total de BioMarin a partir del 1 de julio de 2025. En consecuencia, todas las ofertas pendientes bajo las estanterías fueron terminadas y la compañía está retirando los valores no vendidos de la inscripción conforme a su compromiso bajo la Regla 415.

Esta presentación es principalmente administrativa, señalando el cierre formal de la capacidad de Inozyme para recaudar capital como entidad pública independiente y completando uno de los últimos pasos ante la SEC relacionados con la transacción.

Inozyme Pharma, Inc. (NASDAQ: INZY)는 이전에 유효했던 두 개의 선등록 서류(Form S-3, 번호 333-258702 및 333-275364)에 남아 있던 증권의 등록 말소를 위한 사후 효력 수정안 1호를 제출했습니다. 이 선등록은 보통주, 우선주, 채무, 예탁주식, 청약권, 워런트 및 단위 증권을 합쳐 최대 5억 달러까지 포함하고 있었습니다. 2025년 7월 1일 기준으로 등록된 증권 중 판매 가능한 증권은 남아 있지 않습니다.

이번 수정안은 Inozyme가 BioMarin Pharmaceutical Inc.와의 합병을 완료한 데 따른 것입니다. 2025년 5월 16일자 합병 계약 및 계획에 따라 Incline Merger Sub, Inc.가 Inozyme와 합병되어, 2025년 7월 1일부로 Inozyme는 BioMarin의 완전 자회사로 편입되었습니다. 이에 따라 모든 선등록 하의 미완료 발행은 종료되었으며, 회사는 Rule 415에 따라 미판매 증권을 등록에서 제거하고 있습니다.

이번 제출은 주로 행정적인 절차로, Inozyme가 독립적인 상장 기업으로서 자본 조달 능력을 공식적으로 종료했음을 알리고, 이번 거래와 관련한 SEC의 마지막 단계 중 하나를 완료하는 의미가 있습니다.

Inozyme Pharma, Inc. (NASDAQ : INZY) a déposé l'Amendement post-effectif n° 1 afin de radier les titres restants sous deux déclarations d'enregistrement sur étagère précédemment en vigueur sur le formulaire S-3 (numéros 333-258702 et 333-275364). Ces étagères couvraient collectivement jusqu'à 500 millions de dollars d'actions ordinaires, actions privilégiées, dettes, actions déposées, droits de souscription, bons de souscription et unités. Au 1er juillet 2025, aucun des titres enregistrés n'est plus disponible à la vente.

Cet amendement fait suite à la finalisation de la fusion d'Inozyme avec BioMarin Pharmaceutical Inc. Conformément à l'accord et au plan de fusion datés du 16 mai 2025, Incline Merger Sub, Inc. a fusionné avec Inozyme, faisant d'Inozyme une filiale à 100 % de BioMarin à compter du 1er juillet 2025. Par conséquent, toutes les offres en cours sous les étagères ont été terminées et la société retire les titres invendus de l'enregistrement conformément à son engagement en vertu de la règle 415.

Ce dépôt est principalement administratif, marquant la clôture officielle de la capacité d'Inozyme à lever des fonds en tant qu'entité publique indépendante et complétant l'une des dernières étapes auprès de la SEC liées à la transaction.

Inozyme Pharma, Inc. (NASDAQ: INZY) hat den Nachwirkungsänderungsantrag Nr. 1 eingereicht, um die verbleibenden Wertpapiere unter zwei zuvor wirksamen Shelf-Registrierungserklärungen auf Formular S-3 (Nummern 333-258702 und 333-275364) abzumelden. Die Shelves umfassten insgesamt bis zu 500 Millionen US-Dollar an Stammaktien, Vorzugsaktien, Schuldtiteln, Hinterlegungsscheinen, Bezugsrechten, Optionsscheinen und Einheiten. Zum 1. Juli 2025 sind keine der registrierten Wertpapiere mehr zum Verkauf verfügbar.

Die Änderung erfolgt nach dem Vollzug der Fusion von Inozyme mit BioMarin Pharmaceutical Inc. Gemäß der Fusionsvereinbarung vom 16. Mai 2025 fusionierte Incline Merger Sub, Inc. mit Inozyme, wodurch Inozyme zum 1. Juli 2025 eine hundertprozentige Tochtergesellschaft von BioMarin wurde. Folglich wurden alle ausstehenden Angebote unter den Shelves beendet und das Unternehmen entfernt unverkäufliche Wertpapiere gemäß seiner Verpflichtung unter Regel 415 aus der Registrierung.

Diese Einreichung ist überwiegend administrativer Natur und signalisiert den formellen Abschluss der Kapitalbeschaffungskapazität von Inozyme als eigenständiges börsennotiertes Unternehmen und schließt einen der letzten SEC-Schritte im Zusammenhang mit der Transaktion ab.

As filed with the Securities and Exchange Commission on July 1, 2025

Registration No. 333-258702

Registration No. 333-275364

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO:

FORM S-3 REGISTRATION STATEMENT NO. 333-258702

FORM S-3 REGISTRATION STATEMENT NO. 333-275364

UNDER

THE SECURITIES ACT OF 1933

 

 

INOZYME PHARMA, INC.

(Exact Name of Registrant As Specified In Its Charter)

 

 

 

Delaware   38-4024528

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

321 Summer Street, Suite 400

Boston, Massachusetts, 02210

(857) 330-4340

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

G. Eric Davis

President

Inozyme Pharma, Inc.

321 Summer Street, Suite 400

Boston, Massachusetts, 02210

(857) 330-4340

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Jamie Leigh, Esq.

Ben Beerle, Esq.

Chadwick Mills, Esq.

Siana Lowrey, Esq.

Cooley LLP

3 Embarcadero Center

20th Floor

San Francisco, CA 94111

(415) 693-2000

 

 

Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 relates to the following Registration Statements on Form S-3 (each a “Registration Statement” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Inozyme Pharma, Inc., a Delaware corporation (the “Registrant”) and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereunder under such Registration Statements:

 

   

Registration Statement on Form S-3 (No. 333-258702), which was filed on August 11, 2021 and declared effective by the SEC on August 23, 2021, in relation to the registration of up to $200,000,000 in aggregate principal amount of the Registrant’s common stock, par value $0.0001 per share, preferred stock, par value $0.0001 per share, debt securities, depositary shares, subscription rights, warrants and units.

 

   

Registration Statement on Form S-3 (No. 333-275364), which was filed on November 7, 2023 and declared effective by the SEC on November 15, 2023, in relation to the registration of up to $300,000,000 in aggregate principal amount of the Registrant’s common stock, par value $0.0001 per share, preferred stock, par value $0.0001 per share, debt securities, depositary shares, subscription rights, warrants and units.

On May 16, 2025, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on July 1, 2025, Merger Sub merged with and into the Registrant with the Registrant surviving the merger as a wholly-owned subsidiary of Parent (the “Merger”).

As a result of the Merger, the Registrant has terminated any and all of the offerings and sales of the Registrant’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof, and each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

 


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments No. 1 to the Registration Statements on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, California, on July 1, 2025.

 

Inozyme Pharma, Inc.

By:   /s/ G. Eric Davis
Name:   G. Eric Davis
Title:   President

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

Why did Inozyme Pharma (INZY) file a POS AM on July 1, 2025?

The filing deregisters unsold securities because Inozyme completed its merger with BioMarin Pharmaceutical and ended all standalone offerings.

How much in securities is Inozyme deregistering?

Up to $500 million across two shelf registration statements (Nos. 333-258702 and 333-275364).

What happens to INZY shares after the BioMarin merger?

INZY shares cease independent trading; shareholders receive the merger consideration specified in the May 16, 2025 agreement.

Does this filing affect BioMarin’s financials?

The document itself contains no financial metrics; impact depends on BioMarin’s integration of Inozyme, not on this deregistration.

Are any new securities being offered in this amendment?

No. The amendment removes the ability to offer securities; it does not register additional securities.
Inozyme Pharma, Inc.

NASDAQ:INZY

INZY Rankings

INZY Latest News

INZY Latest SEC Filings

INZY Stock Data

257.60M
63.15M
1.2%
92.62%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON